近日，中国科学院大学杭州高等研究院研究员张夏衡团队与合作企业在《自然》上发表论文，阐述 了他们改造芳香胺的最新研究成果。研究中，他们使用"直接脱氨"新策略，通过廉价试剂将芳香胺中稳 定的碳—氮键替换为功能各异的多种重要化学键，有望规避传统工艺潜在的爆炸风险与重金属污染。这 让从1884年沿用至今的芳香胺应用工艺迎来了新突破，也为解决抗癌药成本难题带来了希望。 该论文从投稿《自然》到正式发表仅用时不到50天，并获得审稿人的高度评价。制药巨头辉瑞公司 高级研发总监斯科特·巴格利在公开审稿意见中称其为"真正的杰作"。 绕开高风险的重氮盐中间体 在微观视角下，很多化合物可以看作由无数"小积木"拼接而成。芳香胺相当于其中的"基础积木"， 在抗癌药物合成等领域有广泛应用，但在拼接过程中，需要将芳香胺原有的氨基去除，将其转化成能拼 接具备各种功能部件的"功能积木"。 在过去的一个多世纪里，工业领域长期沿用一种发明自140年前的传统工艺去除芳香胺的氨基：先 将芳香胺转化为重氮盐中间体，再通过铜盐促进等手段去除氨基，引入新官能团，开展后续转化。传统 工艺的关键问题在于，重氮盐不稳定，具有爆炸危险性。此外，传统工艺还面临铜消耗大 ...

Core Insights - The participation of Sichuan's biopharmaceutical companies in the 2025 World Pharmaceutical Raw Materials Europe Exhibition marks a significant step towards integrating into the global industrial chain [1][3] - Sichuan's exhibition area exceeds 900 square meters, ranking among the top in China's exhibition groups [2] - The delegation consists of 73 local pharmaceutical and related enterprises, with over 150 participants showcasing key products such as specialty raw materials, high-end medical devices, and innovative biopharmaceuticals [1][2] Industry Overview - The World Pharmaceutical Raw Materials Europe Exhibition is the largest and most influential event in the pharmaceutical industry, attracting over 2,500 exhibitors from more than 140 countries and regions [1][2] - The exhibition focuses on green pharmaceuticals and biomanufacturing, aligning well with the development direction of Sichuan's biopharmaceutical industry [2][3] Company Highlights - Notable companies participating include Sichuan Kelun Pharmaceutical, Chengdu Kanghua Biological Products, and Chengdu Beite Pharmaceutical, covering the entire biopharmaceutical industry chain in Sichuan [3] - Sichuan Xinmeijia Biopharmaceutical Co., Ltd. is the largest fish oil producer in China, with significant orders expected during the exhibition, including a projected 30 million yuan in contracts [4] - Chengdu Okang Pharmaceutical Co., Ltd., listed on the Beijing Stock Exchange, is expanding from health food and food additives into the raw materials market [4] Strategic Goals - The event is part of the "Chuanxing Tianxia" international market expansion initiative, aiming to showcase Sichuan's innovative strength and development vitality in the biopharmaceutical sector [1][3] - The strategy emphasizes building networks and strengthening supply chains to enhance international order acquisition and promote high-quality industry development [4]

Core Viewpoint - The article highlights the strategic transformation of Wuchan Zhongda Health, focusing on innovation-driven and green transformation in the pharmaceutical and healthcare sector, aiming to integrate medical services with pharmaceutical manufacturing and investment funds [1][5]. Group 1: Company Transformation - Wuchan Zhongda Health is shifting from a primary focus on medical services to a dual approach that includes pharmaceutical manufacturing and investment funds, emphasizing innovation and green transformation [1]. - Hongyuan Pharmaceutical, a subsidiary, has evolved from a traditional chemical factory to a modern green pharmaceutical enterprise, adopting enzyme-catalyzed processes and eliminating traditional chemical synthesis methods [3][4]. Group 2: Environmental Commitment - The company prioritizes ecological responsibility, integrating pollution reduction and safety into its research and development processes, particularly in the production of atorvastatin intermediates [4]. - Hongyuan Pharmaceutical has achieved significant reductions in resource consumption, with steam usage down by 30%, electricity by 17%, and solvents by 40% [4]. Group 3: Investment and Innovation - Wuchan Zhongda Health is integrating innovation platforms with investment funds to break down barriers between research and application, focusing on the pharmaceutical health industry [5][7]. - The company is developing China's first comprehensive solution for Boron Neutron Capture Therapy (BNCT), which has shown promising results in cancer treatment, with a complete response rate of 46% in Japanese patients [5][6]. Group 4: Future Prospects - The pharmaceutical industry fund is seen as a microcosm of Wuchan Zhongda Health's development of new productive forces, accelerating the layout of innovative drugs and medical devices [7]. - The company aims to enhance its independent research capabilities and integrate technological and industrial innovation to contribute to the economic and social development of Zhejiang Province [7].

Group 1 - The core idea of the article is the innovative transformation of plastic waste into a valuable pain relief medication, acetaminophen, using engineered E. coli bacteria [1][3][4] - The research highlights a novel method of utilizing waste plastic, specifically PET plastic from bottles, as raw material for drug production through metabolic engineering and organic chemistry [3][4] - The process involves breaking down PET into basic molecules, which are then converted into drug precursors within the bacteria, achieving a high yield of 92% for acetaminophen [3][4] Group 2 - This research marks the first successful instance of producing pharmacologically valuable small molecules from discarded plastics within microbial systems, paving the way for advancements in resource recycling and green pharmaceuticals [4] - Future plans include exploring the potential of other types of plastics for similar transformations and identifying additional bacteria capable of such processes, as well as the possibility of producing a wider variety of drugs [4][5] - The vision is to establish "bio-factories" that utilize microorganisms to convert plastic waste into energy, pharmaceuticals, and even food, transforming discarded plastic bottles into valuable raw material "seeds" [5]